Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $17.00 Consensus Price Target from Brokerages

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have been given a consensus rating of “Hold” by the five brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $17.00.

VRCA has been the topic of several research analyst reports. TD Cowen reiterated a “buy” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, January 7th. Loop Capital set a $17.00 target price on Verrica Pharmaceuticals in a research report on Thursday, December 18th. raised Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research report on Thursday, December 18th. Zacks Research downgraded Verrica Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 9th. Finally, Wall Street Zen lowered Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 7th.

Verrica Pharmaceuticals Stock Performance

Shares of VRCA stock opened at $4.38 on Monday. The firm has a market cap of $75.25 million, a price-to-earnings ratio of -2.77 and a beta of 1.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.45 and a current ratio of 2.59. Verrica Pharmaceuticals has a 52 week low of $3.28 and a 52 week high of $9.82. The firm’s 50-day simple moving average is $6.11 and its two-hundred day simple moving average is $5.85.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Wednesday, March 11th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The firm had revenue of $5.09 million for the quarter, compared to analysts’ expectations of $4.52 million. As a group, equities analysts forecast that Verrica Pharmaceuticals will post -1.46 earnings per share for the current year.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several large investors have recently modified their holdings of the business. Affinity Asset Advisors LLC bought a new stake in shares of Verrica Pharmaceuticals in the fourth quarter valued at approximately $5,878,000. Armistice Capital LLC boosted its holdings in Verrica Pharmaceuticals by 75.1% in the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock worth $9,298,000 after buying an additional 479,732 shares during the period. Velan Capital Investment Management LP bought a new position in Verrica Pharmaceuticals in the 4th quarter worth approximately $3,919,000. Boothbay Fund Management LLC purchased a new position in Verrica Pharmaceuticals in the 3rd quarter valued at approximately $1,210,000. Finally, Kalehua Capital Management LLC purchased a new position in Verrica Pharmaceuticals in the 4th quarter valued at approximately $1,959,000. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.